CLOs on the Move

Cingulate

www.cingulate.com

 
The Investor Relations website contains information about Cingulate Incs business for stockholders, potential investors, and financial analysts.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Breckenridge Pharmaceutical

Breckenridge Pharmaceutical Inc. is a Boca Raton, FL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Inkblot Therapy

Inkblottherapy.com offers affordable, secure video counselling any time, any place. We are on a mission to increase accessibility to high quality mental health counselling in Canada.

Mixlab

Mixlab is a modern veterinary pharmacy that specializes in pharmaceutical manufacturing and compounding for veterinary use.

Specialty Operations Solutions

Specialty Operations Solutions, Inc. is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Longboard Pharmaceuticals

Longboard Pharmaceuticals, Inc. (Longboard) is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard was formed in January 2020 by Arena Pharmaceuticals, Inc. (Arena) to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard`s small molecule product candidates were discovered out of the same platform at Arena that represents a culmination of more than 20 years of GPCR research. Longboard is evaluating LP352, an oral, centrally acting, 5-hydroxytryptamine 2c receptor subtype superagonist, in development for the potential treatment of developmental and epileptic encephalopathies. Longboard is also evaluating LP143, a centrally acting, full cannabinoid type 2 receptor agonist, in development for the potential treatment of neurodegenerative diseases associated with neuroinflammation caused by microglial activation, and LP659, a centrally acting, sphingosine-1-phosphate receptor subtypes 1 and 5 modulator, in development for the potential treatment of central nervous system neuroinflammatory diseases.